Dr. Mary J. Cunningham, MD

Dr. Cunningham practices at Upstate University Hospital in Syracuse, New York, part of State University of New York.

Dr. Cunningham's NPI, 1902902760, was assigned on September 16, 2006. Dr. Cunningham graduated from Northwestern University Feinberg Medical School in 1984. Dr. Cunningham holds New York license 185656.

Dr. Cunningham's primary practice is Upstate University Hospital, at 750 East Adams Street, Syracuse, NY 13210 in Onondaga County. The practice phone is (315) 473-4240.

Dr. Cunningham's primary practice is Upstate University Hospital in Syracuse, New York, part of State University of New York. Dr. Cunningham is also affiliated with Crouse Hospital. The medical group on file is University OB/GYN Associates. Dmand AI also links Dr. Cunningham to 3 more hospitals, 1 group practice or clinic and 1 therapy and rehab clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cunningham practices, 7 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Cunningham's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Cunningham is licensed in New York.

CMS data shows 175 Medicare services from Dr. Cunningham across 4 procedure codes in 2024, all of them office visits, for 130 Medicare patients. Medicare paid $10,960 for them. Every service was in an office.

CMS counts 130 Medicare patients who saw Dr. Cunningham in 2024. The largest group is 65 to 74, with 64 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cunningham's median patient age at 66, with 99% women.

In 2024, Dr. Cunningham wrote 108 Medicare Part D claims for 43 patients. 92% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $178 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Cunningham for performance year 2024, reported as part of a group. Dr. Cunningham accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cunningham as offering telehealth. CMS counts 20 procedures of removal of the uterus by Dr. Cunningham, more than 93% of the clinicians it reports for that procedure.

Dmand AI links 4 papers to Dr. Cunningham, published from 2015 to 2023. 2016 was the busiest year, with 2. The most frequent topics are Endometrial Neoplasms, Robotic Surgical Procedures and Lymph Node Excision. Dr. Cunningham has published most often in J Robot Surg. Dr. Cunningham's most frequent co-authors are Paul D. Aridgides, MD, Emily Catherine Daugherty, MD and Esther Dorzin, MD.

Dmand AI links Dr. Cunningham to 10 clinical trials, 4 of them phase 2 studies. 9 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Fallopian Tube Neoplasms and Adenocarcinoma, Clear Cell. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 107 general payments to Dr. Cunningham from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 43% of the total. TESARO, Inc. paid the most, $5,285.

Dr. Cunningham graduated from Northwestern University Feinberg Medical School in 1984.